Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05805605 · ClinicalTrials.gov registry record · Phase 2
Allo HSCT Using RIC and PTCy for Hematological Diseases
A Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT05805605 is a Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 56 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05805605, a Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Peripheral Blood Stem Cell Transplant
- DRUG Allopurinol 300 MG
- BIOLOGICAL Bone Marrow Cell Transplant
Study Locations (1)
Minnesota
- Masonic Cancer Center at University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2028-10-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05805605
The ClinicalTrials.gov registry entry for NCT05805605 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (80% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05805605 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05805605 about?
NCT05805605 is a clinical study titled "Allo HSCT Using RIC and PTCy for Hematological Diseases". This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide...
What is the current status of trial NCT05805605?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2023-05-01. Estimated completion is 2028-10-22.
What conditions does trial NCT05805605 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Acute Lymphocytic Leukemia, Plasma Cell Leukemia.
What interventions are being tested in trial NCT05805605?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Peripheral Blood Stem Cell Transplant (BIOLOGICAL), Allopurinol 300 MG (DRUG), Bone Marrow Cell Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05805605?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05805605 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.